Toll Free: 1-888-928-9744

Hyperoxaluria - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperoxaluria - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides an overview of the Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.

Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate diet and vitamin B-6. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.Hyperoxaluria.

Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperoxaluria (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hyperoxaluria Overview 6 Therapeutics Development 7 Pipeline Products for Hyperoxaluria - Overview 7 Hyperoxaluria - Therapeutics under Development by Companies 8 Hyperoxaluria - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Hyperoxaluria - Products under Development by Companies 11 Hyperoxaluria - Companies Involved in Therapeutics Development 12 Allena Pharmaceuticals Inc 12 Alnylam Pharmaceuticals Inc 13 Dicerna Pharmaceuticals Inc 14 OxThera AB 15 Hyperoxaluria - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 23 ALLN-177 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 ALLN-230 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 ALN-GO1 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 DCR-PHXC - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Oxabact - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Hyperoxaluria - Dormant Projects 31 Hyperoxaluria - Discontinued Products 32 Hyperoxaluria - Product Development Milestones 33 Featured News & Press Releases 33 Oct 04, 2016: Allena Pharmaceuticals and Health Advances Present Analysis of Recurrent Kidney Stone Disease at the Academy of Managed Care Pharmacy Nexus Conference 33 Sep 07, 2016: Allena Pharmaceuticals Strengthens Leadership Team, Names Edward Wholihan as Chief Financial Officer and Robert Alexander, PhD, to Board of Directors 33 May 05, 2016: FDA Grants Orphan Drug Designation to Allena's Investigational Therapy for the Treatment of Pediatric Hyperoxaluria 34 Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria 35 Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week 36 Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015 37 Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria 37 Mar 18, 2015: Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria 38 Nov 17, 2014: Allena Pharmaceuticals Presents Phase 1 Data On ALLN-177 At American Society Of Nephrology Kidney Week 2014 39 Nov 10, 2014: Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014 40 May 15, 2014: OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria 40 Apr 29, 2014: Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones 40 Jan 08, 2014: OxThera Initiates Clinical Trial in Primary Hyperoxaluria 41 Jun 04, 2013: OxThera Strengthens Patent Portfolio For Orphan Disease 42 Jun 07, 2012: OxThera Resumes Clinical Development Of Oxabact For Treatment Of Hyperoxaluria 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 43 Disclaimer 44
List of Tables
Number of Products under Development for Hyperoxaluria, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2016 12 Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 13 Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 14 Hyperoxaluria - Pipeline by OxThera AB, H2 2016 15 Assessment by Monotherapy Products, H2 2016 16 Number of Products by Stage and Target, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Hyperoxaluria - Dormant Projects, H2 2016 31 Hyperoxaluria - Discontinued Products, H2 2016 32



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify